ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches
ORIC Pharmaceuticals shares picked up some ground this week, though the stock is still hanging near the trial-risk levels seen after its prostate cancer update in the spring. U.S. markets now go into a three-day break. Shares on the Nasdaq ended Friday at $8.32, off 1.7% from Thursday’s $8.46. The stock traded as high as $8.70 earlier in the day. But for the week, ORIC was still up about 5% from Monday’s $7.93 finish, according to LSEG data on ORIC’s investor site.